filgrastim + paclitaxel

Filgrastim + paclitaxel is a combination regimen used in oncology, particularly for the management of solid tumors such as breast and gynecologic cancers. Filgrastim is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils to reduce the risk of infection associated with chemotherapy-induced neutropenia. Paclitaxel is a microtubule inhibitor that disrupts cell division, leading to cancer cell death. In clinical practice, filgrastim is administered alongside or following paclitaxel-based chemotherapy regimens to support white blood cell recovery and allow for dose-dense or high-intensity treatment schedules[2][3][5]. This combination does not represent a fixed-dose co-formulation but rather concurrent use as part of supportive care protocols.